Gaochao Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gaochao Guo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chaoyue Li
Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
1 shared publication Hao Liang
Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital
1 shared publication- Hui Guan
Department of Radiation Oncology, The Fourth People’s Hospital of Jinan, Jinan, Shandong Province, China
1 shared publication - Jie Lu
Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
1 shared publication - Jinming Yu
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
1 shared publication Liming Zhao
Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital
1 shared publication
Latest Publications
- Open Access
- 6 July 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1795294
Collateral circulation after revascularization in moyamoya disease: influencing factors and underlying mechanisms
Cerebral revascularization is a primary treatment for moyamoya disease and is generally considered to improve cerebral perfusion while potentially reducing the risk of stroke recurrence. However, the efficiency of postoperative collateral circulation formation varies significantly among individuals, and some patients continue to experience adverse events, such as recurrent ischemia or cerebral hemorrhage, which may be related to inadequate collateralization. Therefore, identifying the factors influencing the formation of collateral circulation after cerebral revascularization is critical for the treatment of moyamoya disease. Previous studies suggest that multiple factors are associated with postoperative collateral vessel formation, including genetic susceptibility (such as the RNF213 p. R4810K variant and microRNA regulation), angiogenic growth factors (such as VEGF, PDGF, and TGF-β1), soluble receptors (e.g., sTie-2), cellular components (including circulating endothelial progenitor cells and mesenchymal stem cells), structural regulators such as Caveolin-1, as well as clinical variables including surgical modality, patient age, and superficial temporal artery blood flow. This article systematically reviews current evidence on factors associated with collateral circulation formation after cerebral revascularization in patients with moyamoya disease, with the aim of informing future research and optimizing treatment strategies.
- 6 July 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1795294
Open AccessCollateral circulation after revascularization in moyamoya disease: influencing factors and underlying mechanisms
Cerebral revascularization is a primary treatment for moyamoya disease and is generally considered to improve cerebral perfusion while potentially reducing the risk of stroke recurrence. However, the efficiency of postoperative collateral circulation formation varies significantly among individuals, and some patients continue to experience adverse events, such as recurrent ischemia or cerebral hemorrhage, which may be related to inadequate collateralization. Therefore, identifying the factors influencing the formation of collateral circulation after cerebral revascularization is critical for the treatment of moyamoya disease. Previous studies suggest that multiple factors are associated with postoperative collateral vessel formation, including genetic susceptibility (such as the RNF213 p. R4810K variant and microRNA regulation), angiogenic growth factors (such as VEGF, PDGF, and TGF-β1), soluble receptors (e.g., sTie-2), cellular components (including circulating endothelial progenitor cells and mesenchymal stem cells), structural regulators such as Caveolin-1, as well as clinical variables including surgical modality, patient age, and superficial temporal artery blood flow. This article systematically reviews current evidence on factors associated with collateral circulation formation after cerebral revascularization in patients with moyamoya disease, with the aim of informing future research and optimizing treatment strategies.
- Open Access
- 18 February 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-13
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
PD-1/PD-L1 checkpoint blockades have achieved significant progress in several kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 expression. However, PD-1/PD-L1 checkpoint blockades have not achieved breakthroughs in treating glioblastoma because glioblastoma has a low immunogenic response and an immunosuppressive microenvironment caused by the precise crosstalk between cytokines and immune cells. A phase III clinical trial, Checkmate 143, reported that nivolumab, which targets PD-1, did not demonstrate survival benefits compared with bavacizumab in recurrent glioblastoma patients. Thus, the combination of a PD-1/PD-L1 checkpoint blockade with RT, TMZ, antibodies targeting other inhibitory or stimulatory molecules, targeted therapy, and vaccines may be an appealing solution aimed at achieving optimal clinical benefit. There are many ongoing clinical trials exploring the efficacy of various approaches based on PD-1/PD-L1 checkpoint blockades in primary or recurrent glioblastoma patients. Many challenges need to be overcome, including the identification of discrepancies between different genomic subtypes in their response to PD-1/PD-L1 checkpoint blockades, the selection of PD-1/PD-L1 checkpoint blockades for primary versus recurrent glioblastoma, and the identification of the optimal combination and sequence of combination therapy. In this review, we describe the immunosuppressive molecular characteristics of the tumour microenvironment (TME), candidate biomarkers of PD-1/PD-L1 checkpoint blockades, ongoing clinical trials and challenges of PD-1/PD-L1 checkpoint blockades in glioblastoma.
- 18 February 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-13
Open AccessChallenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
PD-1/PD-L1 checkpoint blockades have achieved significant progress in several kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 expression. However, PD-1/PD-L1 checkpoint blockades have not achieved breakthroughs in treating glioblastoma because glioblastoma has a low immunogenic response and an immunosuppressive microenvironment caused by the precise crosstalk between cytokines and immune cells. A phase III clinical trial, Checkmate 143, reported that nivolumab, which targets PD-1, did not demonstrate survival benefits compared with bavacizumab in recurrent glioblastoma patients. Thus, the combination of a PD-1/PD-L1 checkpoint blockade with RT, TMZ, antibodies targeting other inhibitory or stimulatory molecules, targeted therapy, and vaccines may be an appealing solution aimed at achieving optimal clinical benefit. There are many ongoing clinical trials exploring the efficacy of various approaches based on PD-1/PD-L1 checkpoint blockades in primary or recurrent glioblastoma patients. Many challenges need to be overcome, including the identification of discrepancies between different genomic subtypes in their response to PD-1/PD-L1 checkpoint blockades, the selection of PD-1/PD-L1 checkpoint blockades for primary versus recurrent glioblastoma, and the identification of the optimal combination and sequence of combination therapy. In this review, we describe the immunosuppressive molecular characteristics of the tumour microenvironment (TME), candidate biomarkers of PD-1/PD-L1 checkpoint blockades, ongoing clinical trials and challenges of PD-1/PD-L1 checkpoint blockades in glioblastoma.